Cspc Ouyi Pharmaceutical Co., Ltd.
Clinical trials sponsored by Cspc Ouyi Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical subsidiary of CSPC Group, developing drugs and generics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a new injection help tackle obesity and diabetes? a safety trial begins
Disease control OngoingThis early-stage trial tests an experimental drug called SYH2069, given as an injection under the skin, in healthy volunteers. The goal is to see if it is safe and how the body processes it at different doses. The study includes people who are overweight or obese, as the drug is …
Phase: PHASE1 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
Disease control OngoingThis Phase 1 trial tests whether a single dose of an experimental drug called SYH2082 is safe and tolerable in healthy adults aged 18 to 55 who are overweight or have obesity. Participants receive either the drug or a placebo injection, and researchers monitor for side effects an…
Phase: PHASE1 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New triple therapy aims to tame type 2 diabetes
Disease control OngoingThis phase 3 trial tests whether adding two new drugs—prusogliptin and dapagliflozin—to standard metformin can improve blood sugar control in adults with type 2 diabetes. About 815 participants who are not well-controlled on metformin alone will receive either the triple combinat…
Phase: PHASE3 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC